口服FLT3抑制剂pexidartinib治疗复发难治FLT3-ITD突变急性髓系白血病的1/2期研究
该1/2期研究评估了口服FLT3抑制剂pexidartinib在复发难治FLT3-ITD突变AML患者中的安全性、耐受性和疗效,共治疗90例患者。未达到最大耐受剂量,推荐2期剂量为3000mg/日,总缓解率为21%,复合完全缓解率为11%,6例成功桥接移植。
要点
- 推荐2期剂量为3000mg/日,基于血浆抑制试验显示该剂量 trough 血浆药物水平可抑制FLT3磷酸化95%。
- 最常见治疗相关不良事件为腹泻(50%)、乏力(47%)和恶心(46%)。
- 总缓解率21%,复合完全缓解率11%,6例成功桥接移植。
核心结论
- pexidartinib在复发难治FLT3-ITD突变AML中显示出一定疗效,推荐2期剂量为3000mg/日,但总缓解率有限。
研究设计与样本
- 1/2期研究,共治疗90例复发难治FLT3-ITD突变AML患者,其中剂量递增部分34例,剂量扩展部分56例,测试剂量为800至5000mg/日分次服用。
主要发现
- 未达到最大耐受剂量,基于药物暴露平台选择3000mg/日为推荐2期剂量。
- 血浆抑制试验显示≥3000mg剂量组 trough 血浆样本可抑制FLT3-ITD AML细胞系中FLT3磷酸化达95%。
- 最常见治疗中出现的不良事件为腹泻(50%)、乏力(47%)和恶心(46%)。
- 6例患者成功桥接至移植;剂量扩展组中位总生存期为112天(90%CI 77-150天),达到完全缓解伴或不伴血细胞计数恢复的缓解者中位总生存期为265天(90%CI 170-422天)。
关键数值与推荐
- 推荐2期剂量为3000mg/日,分次口服。
- 总缓解率21%,复合完全缓解率11%。
- 剂量扩展组中位总生存期112天(90%CI 77-150天),缓解者中位总生存期265天(90%CI 170-422天)。
临床怎么用
- pexidartinib可作为复发难治FLT3-ITD突变AML患者的潜在治疗选择,推荐2期剂量为3000mg/日。
- 治疗中需监测腹泻、乏力、恶心等不良事件。
- 部分患者可通过pexidartinib治疗成功桥接至造血干细胞移植。
局限性
- 研究为1/2期单臂设计,样本量有限,疗效需进一步随机对照研究验证。
- 总缓解率和复合完全缓解率较低,中位总生存期较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitors (TKIs) have activity in acute myeloid leukemia (AML) patients with FLT3 internal tandem duplication (ITD) mutations, but efficacy is limited by resistance-conferring kinase domain mutations. This phase 1/2 study evaluated the safety, tolerability, and efficacy of the oral FLT3 inhibitor PLX3397 (pexidartinib), which has activity against the FLT3 TKI-resistant F691L gatekeeper mutation in relapsed/refractory FLT3-ITD-mutant AML. Ninety patients were treated: 34 in dose escalation (part 1) and 56 in dose expansion (part 2). Doses of 800 to 5000 mg per day in divided doses were tested. No maximally tolerated dose was reached. Plasma inhibitory assay demonstrated that patients dosed with ≥3000 mg had sufficient levels of active drug in their trough plasma samples to achieve 95% inhibition of FLT3 phosphorylation in an FLT3-ITD AML cell line. Based on a plateau in drug exposure, the 3000-mg dose was chosen as the recommended phase 2 dose. The most frequently reported treatment-emergent adverse events were diarrhea (50%), fatigue (47%), and nausea (46%). Based on modified response criteria, the overall response rate to pexidartinib among all patients was 21%. Twenty-three percent of patients treated at ≥2000 mg responded. The overall composite complete response rate for the study was 11%. Six patients were successfully bridged to transplantation. Median overall survival (OS) of patients treated in dose expansion was 112 days (90% confidence interval [CI], 77-150 days), and median OS of responders with complete remission with or without recovery of blood counts was 265 days (90% CI, 170-422 days). This trial was registered at www.clinicaltrials.gov as #NCT01349049.
引用
- Smith CC, Levis MJ, Frankfurt O, et al. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood Adv. 2020. PMID: 32330242. doi:10.1182/bloodadvances.2020001449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。